EU/3/18/1980

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1980) was granted by the European Commission to Orion Corporation, Finland, for levosimendan for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
Levosimendan
Disease / condition
Treatment of amyotrophic lateral sclerosis
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1980

Sponsor's contact details

Orion Corporation
Orionintie 1
02200 Espoo
Finland
Tel. +358 10 426 1
E-mail: clinicaltrials@orionpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating